EIF5A2 Promotes Doxorubicin Resistance in Bladder Cancer Cells through the TGF-β Signaling Pathway

Jinsong Yang, Xue Jiang, Ying Chen, Lisong Teng

PDF(3465 KB)
For Authors|For Editors|For Reviewers
PDF(3465 KB)
Discovery Medicine ›› 2023, Vol. 35 ›› Issue (179) : 1167-1176. DOI: 10.24976/Discov.Med.202335179.113
Article

EIF5A2 Promotes Doxorubicin Resistance in Bladder Cancer Cells through the TGF-β Signaling Pathway

    {{javascript:window.custom_author_en_index=0;}}
  • {{article.zuoZhe_EN}}
Author information +
History +

Highlight

{{article.keyPoints_en}}

Abstract

{{article.zhaiyao_en}}

Key words

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations
{{article.zuoZheEn_L}}. {{article.title_en}}. {{journal.qiKanMingCheng_EN}}. 2023, 35(179): 1167-1176 https://doi.org/10.24976/Discov.Med.202335179.113

References

Publishing order | Descend order by publishing year | Descend order by cited within

References

{{article.reference}}

Funding

RIGHTS & PERMISSIONS

{{article.copyrightStatement_en}}
{{article.copyrightLicense_en}}
PDF(3465 KB)

Accesses

Citation

Detail
Sections
Recommended
Follow Us on
Copyright © 2025.
By using this website, you agree to our Terms & Conditions and Privacy Policy.  
  • Disclaimer
    The statements, opinions and data contained in Discovery Medicine are solely those of the individual authors and contributors and not of the journal and the editor(s). Discovery Medicine stays neutral with regard to jurisdictional claims in published maps and insitutional affiliations.

    • /

    〈 〉